



We Build
Advanced, Affordable and Accessible
Surgical Robotic Solutions



SS Innovations International, Inc.
Company Presentation
June 2026
Nasdaq: SSII



Disclaimers

No Offering of Securities

No offer is made by this Company Presentation (this “**Presentation**”) to invest in SS Innovations International, Inc. (the “**Company**”) or to purchase any of its securities. Any offer to make such an investment or purchase and such investment or purchase will be made only pursuant to definitive offering documentation furnished by the Company.

Forward-Looking Statements

This Presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “**Securities Act**”), and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by our forward-looking statements. Examples of forward-looking statements include statements regarding the benefits, uses and safety of our products, projected financial information, statements of our plans and objectives for future operations and statements concerning proposed new products and services. In some cases, you can identify forward-looking statements by the use of terminology such as “may,” “will,” “should,” “could,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” and other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, performance or achievements. Actual events or results may differ materially. We undertake no obligation to update any of the forward-looking statements after the date of this Presentation to conform them to actual results. Please refer to the risk factors described in the “Risk Factors” section and other sections included in the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the SEC.

Statistical and Other Industry and Market Data

This Presentation includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties as well as our own estimates of potential market opportunities. All of the market data used in this Presentation involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. Our estimates of the potential market opportunities for our product candidates include several key assumptions based on our industry knowledge, industry publications, third-party research and other surveys, which may be based on a small sample size and may fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, and management is responsible for the accuracy of such assumptions and data, no independent source has verified such assumptions.

Our Vision

To continuously improve and deploy our **technologically-advanced, cost-effective** surgical robotic systems, while maintaining **affordability** and **accessibility** for the benefit of a larger segment of patients globally



Advanced . Affordable . Accessible
Robotic Surgery

Snapshot of SS Innovations

- We develop innovative, **differentiated surgical robotic technologies**, highlighted by our:
 - Proprietary **surgical robotic system**, the **SSi Mantra 3**;
 - **Comprehensive suite of surgical instruments**, which support a variety of surgical procedures, including **robotic cardiac surgery**;
 - AI- and XR-driven **imaging, training and simulation platform**; and
 - Pioneering **telesurgery** capabilities.
- We are backed by a team of leading **surgical robotics experts** and seasoned medical technology executives.
- We are a rapidly growing American company with Indian roots, **expanding globally** and preparing for a potential strategic entry into **Europe** and the **United States**.
- Including the Company's strong foundational market of India, the SSi Mantra installed base currently spans **12** countries.

11,270

Multi-Specialty Surgeries

210

SSi Mantra Systems Installed

9

Surgical Specialities

186

Hospitals

174

Validated Surgical Procedures

171

Telesurgeries

587


Robotic Cardiac Surgeries

2022

Year of Commercialization


0

of Significant Safety Events Reported




Note: Data as of May 31, 2026

Snapshot of SS Innovations (Continued)



Headquarters	Gurugram, India
Company Domicile	Florida, USA
Employees (May 31, 2026)	479
Year Merged with Avra Medical	2023
Year Uplisted to Nasdaq	2025
Ticker	SSII
Exchange	Nasdaq-CM
Shares Out (June 12, 2026)	200.1 mm
Recent Price (June 12, 2026)	\$3.36
Market Cap (June 12, 2026)	\$0.7 bn
Insider Ownership (June 12, 2026)	~72%



Investment Highlights

- 1** Distinguished Leadership and Board with Proven Track Record in Surgical Robotics Technology
- 2** Large and Growing Total Addressable Market with Favorable Industry Tailwinds
- 3** Advanced, Cost-Efficient Surgical Robotics Platform – Clinically and Commercially Differentiated
- 4** Established Presence in India with Global Expansion Underway
- 5** Strong Sales Growth with an Increasing Mix of Recurring Consumables Revenue and Expanding Margins
- 6** Strategy to Deliver Long-Term, Sustainable Growth

Distinguished Leadership and Board with Proven Track Record in Surgical Robotics Technology



Sudhir Srivastava, MD, Founder, Chairman & CEO

- Robotic cardiac surgeon with 40+ years of experience
- Pioneered many of the world's first robotic cardiac procedures
- Performed numerous robotic cardiac surgeries and trained surgical teams worldwide
- University of British Columbia, University of Chicago, Alliance Hospital
- Owns 108,596,261 shares, or 54.3% of SSII shares outstanding¹



Vishwajyoti Srivastava, MD, Chief Executive Officer, APAC & Board Member

- Led the development of the OMNI 3D Medical Visualization system
- Serves as the President of OMNI 3D HD to advance existing technological platform for availability in the global surgical and endoscopic marketplace
- Previously served as the VP of Marketing and Technology at the International Centre for Robotic Surgery in New Delhi
- Columbia University, Saint James School of Medicine




Frederic Moll, MD, Vice-Chairman

- Former Chief Development Officer, J&J Medical Devices
- Founder, Intuitive Surgical, Hansen Medical, Auris Health
- Co-Founder & Partner, Sonder Capital Management
- Board Member, PROCEPT BioRobotics, Neptune Medical, Moon Surgical
- Former Board Member, Shockwave Medical, Restoration Robotics, Intersect ENT
- Owns 20,836,298 shares, or 10.4% of SSII shares outstanding¹



Tim Paul Adams, Board Member

- Regional Operating Officer, Ascension
- Former Regional CEO, Tenet Healthcare
- Chairman, Tennessee Hospital Association




Barry Cohen, COO - Americas & Board Member

- Co-Founder, CEO and Director, Avra Medical Robotics
- Former Director and President, Synalloy Corp.
- Former Chairman of the Board, Wolverine Technologies



Dr. Mylswamy Annadurai, Board Member

- Former Director, Indian Space Research Organization




Somashekhar SP, MD, Board Member

- Robotic Surgeon
- Global Director, Aster International Institute of Oncology

Large and Growing Addressable Market with Favorable Industry Tailwinds

Accelerated Global Adoption of Robotic Surgery



Key Market Trends

Technology

Innovation and enhanced capabilities make next-generation systems versatile across a broad spectrum of surgeries

Demographics

Aging global population driving increased need for surgical interventions

Disease Burden

Growing incidence of chronic and lifestyle diseases

Workforce Challenges

Helps address increasing shortage of trained healthcare workers, by reducing labor intensity across each care episode

Economics

Improved economics for providers and payers

Patient Benefits

Reduced patient trauma, shorter recovery times, and enhanced patient outcomes

Surgeon Benefits

Ergonomic systems reduce staff fatigue and enhanced training pathways across varying skill levels improves adoption

Hospital Benefits

Improved resource utilization, increased revenue, reduced cost with lower complication rates and shorter lengths of stay

SSII aims to accelerate access to surgical robotics in underserved regions of the world

Large and Growing Addressable Market with Favorable Industry Tailwinds

Access to Robotic Surgery Remains Limited

Benefits of Robotic Surgery

Greater Precision

Minimal Blood Loss

Faster Recovery

10x Magnified 3D vision

Less Pain and Discomfort

Reduced Surgeon Fatigue

Smaller Incisions on Patients

Reduced Risk of Infection

In the 20 Years Since Launch of Robotic Surgery, Access Remains Limited

Installed base largely limited to the US, EU and Japan

Only 5% of installed systems are "available" to ~7 billion people outside the US, EU and Japan

Less than 1% of surgical procedures worldwide each year are performed robotically¹

Key Challenges of Existing Systems

High cost of acquisition and implementation

Absence of trained personnel

Unattractive economics for hospitals with lower volumes

Lack of versatility and adaptability of systems and limited systems with multi-specialty capabilities

Large and Growing Addressable Market with Favorable Industry Tailwinds

Unmet Needs and Market Opportunity Support Our Foundational Market in India

~1.4 Billion
Population

~70,000
Hospitals


1.5 Hospital Beds
per 1,000 people
(compared to the
recommended 3)¹

Estimated need of **5,000**
surgeries per year per
100,000 people²

950 robotic-assisted trained surgeons and **>180**
da Vinci robotic-assisted surgical systems installed
across major private and government hospitals³

>100,000 da Vinci
procedures performed⁶

Global surgical robotics market is
expected to reach **\$27.1 billion** USD by
2030⁵



11,270⁴
Robot Assisted Surgeries
performed in India
on the SSi Mantra

194⁴
Surgical Robotic Systems are
SSi Mantra

Estimated 2,100+⁴
Robotic Surgeons trained
on the SSi Mantra

Advanced, Cost-Efficient Surgical Robotics Platform

SSi Mantra 3

3 Vision Cart

3D 4K resolution monitor, identical to the surgeon's console, for OR staff. Also houses the control system for the articulating endoscope and camera and pre-operative guidance software

3

2

2 Patient-Side Robotic Arm Carts

Modular robotic arms mounted on individual carts with the option of using 3, 4 or 5 robotic arm configurations

4

1 Surgical Command Center

Ergonomic open-faced console comprised of a pair of passive 3D glasses, a 3D 4k resolution monitor and a 2D touch monitor for system controls

1

4 Instrument and Accessories

Comprehensive suite of stapling, energy and core instrumentation for the surgical system under the brand name SSi Mudra

4



Advanced, Cost-Efficient Surgical Robotics Platform

SSi Mantra 3 – Surgical Command Center



Ergonomic Open-Faced
Console

Large 3D 4K Monitor

Large 2D Touch Monitor
for System Controls and
DICOM access

Lightweight Magnetic
Hand Controls Design


Head Tracking
Safety Feature

Digital Ergonomics
Control

Tele Surgery and
Tele Proctoring Enabled

Advanced, Cost-Efficient Surgical Robotics Platform

SSi Mantra 3 – Patient Side Robotic Arm Carts



Modular
Robotic Carts

Freedom of
Patient Docking

3/4/5
Patient Cart
Connectivity

Absolute Stability
Parking Locks

Smaller Individual
Cart Footprint

Advanced Touch
Screen Controls

Advanced, Cost-Efficient Surgical Robotics Platform

SSi Mudra – Multi Specialty Robotic Instruments

40+¹
Types of
Instruments


7 Degrees of Freedom
Articulating Robotic
Instruments

10 Use
Life Cycle
per Instrument


Novel Instrument:
**Automated Coronary
Anastomotic
Connector¹**



Novel Instrument:
**Multi-Fire Clip
Applier²**



Advanced Instruments:
Selicut Harmonic



Advanced Instruments:
**ExpertSeal
Vessel Sealer**



Advanced Instruments:
**Anastoflex
Stapler**




On January 6, 2026, the Company announced the development of **five new 5-millimeter surgical robotic instruments** for clinical use across multiple specialties, including **pediatric**, **cardiac**, and **head and neck** surgery, among other procedures involving smaller anatomical structures.

20+¹

Cardiac Specialty Instruments

Only company in the world **actively advocating** for robotic cardiac surgery
Untapped market potential in **automated coronary artery bypass surgery**
400+ complex robotic cardiac surgeries performed with the SSI Mantra




Advanced, Cost-Efficient Surgical Robotics Platform

SSi Maya – Enhancing Surgical Capabilities with Mixed Reality and AI Enabled Technologies

SSi Guru

XR Tele Proctoring System

- Mixed Reality Headset
- Portable 3D Surgery Viewer
- Interactive Virtual Screens
- CDSCO Approved
- Virtual Tele Illustration Feature
- Proctored over 1,200 miles under 400 ms latency



AR Smart Glasses¹

3D Visualization System

- 3D HD 1080p vision
- Variable IPD adjustments
- Direct from endoscope video signal processing
- IMU based head tracking



Cognitive Skill Simulator¹

A different approach to train surgeons

- Overlaid instruments tracking
- Guided procedure steps
- Trains cognition and muscle memory
- Enhancing motor skills through repetition
- Console and VR based learning system



Mixed reality-powered and AI-enabled technologies for better training, visualization, and simulation for the entire surgical team.

Advanced, Cost-Efficient Surgical Robotics Platform


Pioneering Telesurgery Capabilities and Mobile Robotic Telesurgery Unit



SSI MANTRAM



171 telesurgeries have been completed with the SSI Mantra surgical robotic system²



First system approved for telesurgery in India.¹ We enhance remote surgical access and empower underserved communities through telesurgery, surgical education, mentoring, and real-time data insights.

March 2026 -
SSI Mantra approved for telesurgery in **Indonesia** and the **Philippines**

1. CDSCO approval (India)
2. As of 5/31/26
3. Communication line distance

Advanced, Cost-Efficient Surgical Robotics Platform

The SSi MantrAsana Tele-Surgeon Console Facilitates Telesurgery from “Anywhere”

SSi MantrAsana Tele-Surgeon Console



Compact Self-Contained Chair

Inbuilt Electronics

Magnetic Sensor-Based Controls

Lightweight Glasses

Magnified Three-Dimensional View

Enables Portability

Requires Less Space

Facilitates Telesurgery from Physician's Offices and other Locations with Limited Working Space

Established Presence in India with Global Expansion Underway

World-Class R&D and Manufacturing Facilities to Support Growth and Cost Efficiency

R&D, Manufacturing,
Assembly, and Operations
in Gurgaon, Delhi
**National Capital Region
(India)**

Proximity to
**New Delhi
International airport**
with excellent
connectivity with all
parts of the world

~91,000 sq ft space
spread over three floors
as of May 31, 2026

Manpower of **479**
as of May 31, 2026

20 Systems per month
Current Production Capacity


Plan to expand
manufacturing to match
growth



Established Presence in India with Global Expansion Underway


SSi Mantra 3 Is Demonstrating Rapid Adoption Across Various Geographies

Overview of Installed Base




 Installed base  Academic center

Cumulative Installed Base




Completed Procedures



Established Presence in India with Global Expansion Underway

Global Expansion - Regulatory Approvals




In 2025, SS Innovations generated approximately **87%** of its revenue from **India**.

We expect the percentage of total revenue coming from the **rest of the world** to significantly expand over time.


Established Presence in India with Global Expansion Underway

Estimated Regulatory Timelines

US FDA






EU CE Mark




Notified body – SZUTEST, Germany

1. Human factor validation in the US
2. Dependent on the outcome of the review process

Strong Sales Growth with an Increasing Mix of Recurring Consumables Revenue and Expanding Margins



First Quarter 2026 – Robust Growth in Revenue and SSi Mantra Installations and Procedures



Growth Strategy

Platform Value

- Advanced Technology
- Lower Cost
- Ease of Training
- Improved Patient Outcomes
- Differentiated Features (e.g., Cardiac)

Focus on Large Multi-Specialty Hospitals

- Secure Initial Placements
- Expand # of Physicians using Mantra 3
- Increase System Utilization at Each Hospital
- Place Additional Systems at Each Hospital (Go Deeper)

Target **Leading Surgeons and Thought Leaders** to Raise Awareness and Encourage Widespread Adoption

- Indian Medical Advisory Board
- International Advisory Board
- Medical Conferences
- Robotic Surgery Training Programs
- Strategic Partners (e.g., Johns Hopkins)

Continuously Improve and Innovate Our Top-Tier Robotics Platform through **New Product Development** and **Enhanced Technology**.

Maintain **Stronghold in India**, Grow in **Select Underserved Countries** with Low Penetration and Cost Barriers, and Pursue **Established Markets**.

In the **United States**, after FDA approval Focus on **ASCs** and **Smaller Hospitals** while Leveraging the SSi Mantra's Differentiated **Cardiac** Surgery Capabilities.

Appendix

FY 2023 – FY 2025 Financial Summary


SS Innovations Statement of Operations (in USD)	Twelve Months Ended			Three Months Ended	
	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2025	March 31, 2025	March 31, 2026
Revenue	5,875,314	20,649,528	42,484,747	5,120,610	11,101,366
Gross Profit	725,528	8,452,366	19,544,255	1,087,208	5,327,221
<i>Gross margin</i>	12.3%	40.9%	46.0%	21.2%	48.0%
Operating (loss) income	(20,273,984)	(18,975,962)	(8,194,034)	(5,921,853)	(3,638,757)
Net (loss) income	(20,878,292)	(19,151,197)	(8,160,947)	(5,681,353)	(3,582,571)
Diluted EPS	\$(0.14)	\$(0.11)	\$(0.06)	\$(0.03)	\$(0.02)
Diluted shares	152,069,825	181,203,673	198,699,461	188,599,859	205,309,556

Balance Sheet (in USD)	March 31, 2026
Cash ¹	23,611,050
Current assets	66,261,517
Total assets	90,546,889
Current liabilities	26,045,003
Long term debt	-
Total stockholders' equity	54,523,413

Summary of SSi Mantra Installations


Annual Installations

Year	#	Growth
2022	3	-
2023	15	400%
2024	47	213%
2025	103	119%




Cumulative Installations¹

Year	#	Growth
2022	3	-
2023	18	500%
2024	65	261%
2025	168	158%



Quarterly Installations

Year	#	Growth
Q1'24	9	-
Q2'24	10	-
Q3'24	6	-
Q4'24	22	-
Q1'25	15	67%
Q2'25	23	130%
Q3'25	27	350%
Q4'25	38	73%
Q1'26	26	73%



Investor Contact:

EQUITY GROUP

Kalle Ahl, CFA

(303) 953-9878

kalle.ahl@theequitygroup.com



www.ssinnovations.com

investors@ssinnovations.org